Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.66 |
| ▸ | FFAR3 | O14843 | 11/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | HPGD | P15428 | 4/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3242208 | 0.85 | FFAR3 (0.70) | HSD17B10KDM4EFFAR3ALDH1A1HPGD | |
| SCHEMBL2998592 | 0.77 | KDM4E (1.00) | HSD17B10KDM4EFFAR3ALDH1A1HPGD | |
| SCHEMBL3324020 | 0.73 | KDM4E (0.78) | HSD17B10KDM4EFFAR3ALDH1A1HPGD | |
| SCHEMBL3326098 | 0.73 | KDM4E (0.80) | HSD17B10KDM4EFFAR3ALDH1A1HPGD | |
| SCHEMBL7817207 | 0.71 | HSD17B10 (0.65) | HSD17B10KDM4EFFAR3ALDH1A1HPGD | |
| SCHEMBL3250425 | 0.70 | FFAR3 (0.70) | HSD17B10KDM4EFFAR3ALDH1A1HPGD | |
| SCHEMBL3320570 | 0.70 | KDM4E (0.75) | HSD17B10KDM4EFFAR3ALDH1A1HPGD | |
| SCHEMBL5064643 | 0.70 | FFAR3 (1.00) | KDM4EFFAR3 | |
| SCHEMBL5202041 | 0.69 | FFAR3 (0.76) | HSD17B10KDM4EFFAR3ALDH1A1HPGD | |
| SCHEMBL2990862 | 0.67 | KDM4E (0.66) | HSD17B10KDM4EFFAR3ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045428-B2 | Substituted heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-8716319-B2 | Substituted heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130324525-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-20100197684-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD PALO ALTO, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| WO-2010002483-A1 | OPTIONALLY CONDENSED DIHYDRO PYRIDINE, DIHYDROPYRIMIDINE AND DIHYDRO PYRANE DERIVATIVES ACTING AS LATE SODIUM CHANNEL BLOCKERS | CV THERAPEUTICS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| US-20090181986-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | CV THERAPEUTICS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-20090012103-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. | 2009-01-08 | — | — | US | disclosed |
| WO-2009006580-A1 | OPTIONALLY CONDENSED DIHYDROPYRIDINE, DIHYDROPYRIMIDINE AND DIHYDROPYRANE DERIVATIVES ACTING AS LATE SODIUM CHANNEL BLOCKERS | CV THERAPEUTICS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197684-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | NQO1, GPR119, GLP1R | HSD17B10 537/4885KDM4E 1088/4885FFAR3 399/4885 |
| US-20130324525-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | NQO1, GPR119, GLP1R | HSD17B10 537/4885KDM4E 1088/4885FFAR3 399/4885 |
| US-20090181986-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | NQO1, GPR119, GLP1R | HSD17B10 537/4885KDM4E 1088/4885FFAR3 399/4885 |
| US-20090012103-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | NQO1, GPR119, GLP1R | HSD17B10 537/4885KDM4E 1088/4885FFAR3 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.